Janney Montgomery’s healthcare analyst Chiara Russo was out pounding the table on BioDelivery Sciences International, Inc. (NASDAQ:BDSI), reiterating a Buy rating and price target of $19, which represents a potential upside of 185% from where the stock is currently trading.

Russo noted, “The FDA has approved the new formulation of Onsolis, a product that uses the same unique buccal delivery technology as currently marketed Bunavail. This is another positive for the name, which has struggled in the first half of the year due to the lagging Bunavail launch; however we stand by our thesis that 2H15 is the reason to own the name with Bunavail RXs finally showing meaningful ramp, the Onsolis approval and of course the big Oct 23rd PDUFA for Belbuca.”

“Belbuca for pain is where we continue to place the majority of our value with it’s Oct 23rd PDUFA data with $12/share, Bunavail makes up $5.5/share with cash (end of 2015) and technology value being the remaining $1.5/share,” the analyst added.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Chiara Russo has a total average return of 23.4% and a 62.5% success rate. Russo has a 21.9% average return when recommending BDSI, and is ranked #669 out of 3737 analysts.

All the 8 analysts polled by TipRanks rate Biodelivery Sciences stock a Buy. With a return potential of 184.4%, the stock’s consensus target price stands at $18.80.